公共卫生——赵迎泽

　　一、个人简介

　　赵迎泽，博士，副研究员，公共卫生硕士生导师。2010年获重庆医科大学临床检验诊断学专业博士学位，2010-2016年分别在中国医学科学院基础医学研究所和中国科学院动物研究所从事博士后研究工作。2016年至今，在中国疾病预防控制中心病毒病预防控制所高福院士实验室工作，主要从事病原感染的细胞免疫应答机制和免疫治疗策略研究。以第一作者（含共同第一作者）或通讯作者，在Immunity、Innovation、The Journal of Immunology、The Lancet Regional Health–Western Pacific、iScience、Cellular & Molecular Immunology、Nucleic Acids Research、Molecular Therapy Nucleic Acids等国际期刊发表研究论文10余篇。获得博士后基金一等资助，主持国家自然科学基金青年基金1项，作为项目骨干主持和参与多项国家自然科学基金项目、国家科技重大专项和重点研发计划。曾于2019年赴非洲塞拉利昂开展抗击埃博拉技术援助工作。

　　二、主要研究方向

　　1.病原感染的细胞免疫应答机制研究。

　　2.免疫治疗策略研究。

　　三、代表性论文、成果

　　1. Jianhua Yin#, Yingze Zhao#, Fubaoqian Huang#, Yunkai Yang#, Yaling Huang#, Zhenkun Zhuang#, Yanxia Wang#, Zhifeng Wang, Xiumei Lin, Yuhui Zheng, Wenwen Zhou, Shuo Wang, Ziqian Xu, Beiwei Ye, Yaxin Guo, Wenwen Lei, Lei Li, Jinmin Tian, Jinxian Gan, Hui Wang, Wei Wang, Peiyao Ma, Chang Liu, Xiaoyu Wei, Xuyang Shi, Zifei Wang, Yang Wang, Ying Liu, Mingming Yang, Yue Yuan, Yumo Song, Wen Ma, Zhuoli Huang, Ya Liu, Yunting Huang, Haorong Lu, Peipei Liu, Hao Liang, Yong Hou, Xun Xu, Longqi Liu, Yuntao Zhang*, Guizhen Wu*, George F. Gao*, Xin Jin*, Chuanyu Liu*, Xiaoming Yang*, William J. Liu*. Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine. Innovation. 2023 Jan 30;4(1):100359. (IF=32.1)

　　2. Yingze Zhao#, Wenling Xiao#, Yanan Wu#, Wenhui Fan#, Lei Li, Can Yue, Qingxu Zhang, Danni Zhang, Xiaoju Yuan, Sijia Yao, Sai Liu, Min Li, Pengyan Wang, Hangjie Zhang, Jie Zhang, Min Zhao, Xiaoqun Zheng, Wenjun Liu*, George F. Gao*, William J. Liu*. Parallel T cell immunogenic regions in IBV and IAV with distinct nuclear export signal functions: the balance between viral life cycle and immune escape. J Immunol. 2023 Apr 15;210(8):1074-1085. (IF=4.4)

　　3. Yingze Zhao#, Xin Zhao#, Rong Zhang#, Beiwei Ye#, Xiaoju Yuan, Danni Zhang, Lei Li, Jinmin Tian, Yaxin Guo, George F. Gao*, William J. Liu*. Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: a preliminary observation. Lancet Reg Health West Pac. 2022 Apr 01;21:100440. (IF=7.1)

　　4. Yingze Zhao#, Mingwei Sun#, Nan Zhang#, Xueyuan Liu, Can Yue, Lei Feng, Shushen Ji, Xiao Liu, Jianxun Qi, Catherine C.L. Wong*, George F. Gao*, William J. Liu*. Phosphosite-dependent Presentation of Dual Phosphorylated Peptides by MHC Class I Molecules. iScience. 2022 Apr 15;25(4):104013. (IF=5.8)

　　5. Jia Lu#, Chen Zhao#, Yingze Zhao#, Jingfang Zhang#, Yue Zhang, Li Chen, Qiyuan Han, Yue Ying, Shuai Peng, Runna Ai, Yu Wang. Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. Nucleic Acids Res. 2018 Mar 16;46(5):e25. (IF=11.147)

　　6. Chen Zhao#, Yingze Zhao#, Jingfang Zhang#, Jia Lu, Li Chen, Yue Zhang, Yue Ying, Junjun Xu, Shixian Wei, Yu Wang. HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control. Mol Ther Nucleic Acids. 2018 Dec 7;13:208-219. (IF=5.919)

　　7. YingZe Zhao#, Xiao-Ling Liu#, Guo-Min Shen, Yan-Ni Ma, Feng-Lin Zhang, Ming-Tai Chen, Hua-Lu Zhao, Jia Yu, Jun-Wu Zhang. Hypoxia induces peroxisome proliferator-activated receptor γ expression via HIF-1-dependent mechanisms in HepG2 cell line. Arch Biochem Biophys. 2014 Feb 1;543:40-7. (IF=2.8)